Mirna Therapeutics, Inc., is a biopharmaceutical research and development company focused on miRNA-directed human therapies. The Company was founded in late 2007 to accelerate the drug discovery and development program that began in 2002 at Ambion, Inc., The RNA Company, and was continued at Asuragen, Inc., a leading company developing diagnostic products based on RNA and DNA. Mirna has identified numerous tumor suppressor miRNAs that play key roles in preventing normal cells from becoming cancerous. These miRNAs are reduced or lost in virtually all cancers. Mirna’s therapeutic strategy is to bring this tumor suppressor activity back into target tissue cells by administering mimics of natural miRNAs, an approach known as miRNA Replacement Therapy. Replacement of one or more of these key miRNAs results in a strong therapeutic response in animals, supporting the emerging consensus that the systemic administration of miRNAs may be a clinically viable anticancer therapeutic strategy. Mirna is creating value by broadening its base of miRNA intellectual property, identifying new miRNA therapeutic targets, and advancing the development of several miRNA drug leads to validated drug candidates directed against cancerous disease. Mirna is pursuing partnerships with pharmaceutical and biotechnology companies to leverage its intellectual property and expand the Company’s development pipeline in oncology which includes traditionally structured drug discovery and development collaborations, research and technology collaborations, and intellectual property licenses. The Company’s intellectual property and research platforms also apply to diseases other than cancer, providing opportunities for partnerships outside the cancer space.